Clinic for Internal Medicine, Lugano Regional Hospital, Ente Ospedaliero Cantonale, Lugano, Switzerland.
Division of Endocrinology, Hospital de Clínicas José de San Martin, University of Buenos Aires, Buenos Aires, Argentina.
Front Endocrinol (Lausanne). 2022 Jun 23;13:900964. doi: 10.3389/fendo.2022.900964. eCollection 2022.
After the beginning of COVID-19 vaccination campaigns, several reports of thyroid disease possibly related to the COVID-19 vaccination progressively appeared in the literature, raising the question of whether the thyroid disorder might be a SARS-CoV-2 vaccine complication. The aim of this study was to analyze the data about COVID-19 vaccination and thyroid disease, evaluate the size and quality of related literature, assess the type of these events, and investigate their timing of onset with respect the vaccination. Pubmed/MEDLINE and Cochrane were systematically reviewed until February 2022 to retrieve the largest number of original papers, case reports, and case series articles reporting thyroid disease after SARS-CoV-2 vaccination. Forty-six articles were included with a total of 99 patients aged from 26 to 73 years were described, of whom 74.75% female. Regarding the vaccination received, 49.49% of patients received Comirnaty (Pfizer/BioNTech), 14.14% CoronaVac (Sinovac), 12.12% Vaxzevria (Oxford/Astrazeneca), 11.11% Spikevax (Moderna), 3.03% Ad26.COV2.S (Janssen, Johnson & Johnson), one patient Covaxin (Bharat Biotech) and one patient Convidecia (Cansino). In 7 cases the thyroid disorder developed after the third dose with a combination of different vaccines. Regarding the type of thyroid disorder, 59 were subacute thyroiditis (SAT), 29 Graves' disease (GD), 2 co-occurrence of SAT and GD, 6 painless thyroiditis (PT), and single cases of thyroid eye disease and hypothyroidism associated with mixedema. The timeline between vaccination and thyroid disorder ranged between 0.5 to 60 days, with an average of 10.96 days. Considering the limited follow-up time, a complete remission was reported in most of SAT and PT cases while a persistence was observed in GD. In conclusion, both size and quality of published data about thyroid inconveniences after COVID-19 vaccination are limited; thyroid disorders may occur within 2 months after COVID-19 vaccination; among all thyroid diseases after COVID-19 vaccination, GD and SAT seem to be more frequent.
在 COVID-19 疫苗接种运动开始后,文献中逐渐出现了几例与 COVID-19 疫苗接种相关的甲状腺疾病报告,这引发了一个问题,即甲状腺疾病是否可能是 SARS-CoV-2 疫苗的并发症。本研究旨在分析 COVID-19 疫苗接种和甲状腺疾病的数据,评估相关文献的数量和质量,评估这些事件的类型,并研究它们相对于疫苗接种的发病时间。系统检索了 Pubmed/MEDLINE 和 Cochrane,直到 2022 年 2 月,以检索到最大数量的报告 SARS-CoV-2 疫苗接种后甲状腺疾病的原始论文、病例报告和病例系列文章。共纳入 46 篇文章,共描述了 99 例年龄在 26 至 73 岁的患者,其中 74.75%为女性。关于接种的疫苗,49.49%的患者接种了 Comirnaty(辉瑞/生物科技),14.14%接种了 CoronaVac(科兴),12.12%接种了 Vaxzevria(牛津/阿斯利康),11.11%接种了 Spikevax(莫德纳),3.03%接种了 Ad26.COV2.S(杨森,强生),1 例患者接种了 Covaxin(巴拉特生物技术公司),1 例患者接种了 Convidecia(康希诺)。7 例甲状腺疾病发生在接种第三剂不同疫苗后。关于甲状腺疾病的类型,59 例为亚急性甲状腺炎(SAT),29 例为格雷夫斯病(GD),2 例 SAT 和 GD 同时发生,6 例为无痛性甲状腺炎(PT),还有 1 例甲状腺眼病和与黏液性水肿相关的甲状腺功能减退症。接种疫苗与甲状腺疾病之间的时间间隔为 0.5 至 60 天,平均为 10.96 天。考虑到随访时间有限,SAT 和 PT 病例大部分报告完全缓解,而 GD 病例则持续存在。总之,COVID-19 疫苗接种后甲状腺不适的发表数据在数量和质量上都有限;甲状腺疾病可能在 COVID-19 疫苗接种后 2 个月内发生;在 COVID-19 疫苗接种后所有甲状腺疾病中,GD 和 SAT 似乎更为常见。